These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 15087065)

  • 21. Myelodysplastic syndrome in children and adolescents.
    Niemeyer CM; Baumann I
    Semin Hematol; 2008 Jan; 45(1):60-70. PubMed ID: 18179970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapamycin is highly effective in murine models of immune-mediated bone marrow failure.
    Feng X; Lin Z; Sun W; Hollinger MK; Desierto MJ; Keyvanfar K; Malide D; Muranski P; Chen J; Young NS
    Haematologica; 2017 Oct; 102(10):1691-1703. PubMed ID: 28729300
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Innate immune signaling in the myelodysplastic syndromes.
    Starczynowski DT; Karsan A
    Hematol Oncol Clin North Am; 2010 Apr; 24(2):343-59. PubMed ID: 20359630
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Myelodysplastic syndrome associated with monosomy 7 in childhood: a retrospective study.
    Aktas D; Tuncbilek E
    Cancer Genet Cytogenet; 2006 Nov; 171(1):72-5. PubMed ID: 17074595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acquired aplastic anemia.
    Keohane EM
    Clin Lab Sci; 2004; 17(3):165-71. PubMed ID: 15314891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunologic abnormalities in myelodysplastic syndromes.
    Hamblin T
    Hematol Oncol Clin North Am; 1992 Jun; 6(3):571-86. PubMed ID: 1613007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A patient with paroxysmal nocturnal hemoglobinuria, T cell large granular lymphocyte clonal expansion, and monoclonal gammopathy of undetermined significance.
    Fukumoto JS; Gotlib J
    Am J Hematol; 2006 Nov; 81(11):870-4. PubMed ID: 16929542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New agents in myelodysplastic syndromes.
    Jabbour EJ; Giles FJ
    Curr Hematol Rep; 2005 May; 4(3):191-9. PubMed ID: 15865871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunosuppressive therapy for myelodysplastic syndromes.
    Dobbelstein C; Ganser A
    Curr Pharm Des; 2012; 18(22):3184-9. PubMed ID: 22571697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Refractory anemia and the myelodysplastic syndromes.
    Lawrence LW
    Clin Lab Sci; 2004; 17(3):178-86. PubMed ID: 15314893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. T-cell large granular lymphocyte proliferation in myelodysplastic syndromes: Clinicopathological features and prognostic significance.
    Zhang X; Sokol L; Bennett JM; Moscinski LC; List A; Zhang L
    Leuk Res; 2016 Apr; 43():18-23. PubMed ID: 26927701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Paroxysmal nocturnal hemoglobinuria associated with in vitro inhibition of erythropoiesis by bone marrow T lymphocytes.
    Merchav S; Tatarsky I; Chezar J; Sharon R; Rosenbaum H; Schechter Y
    Isr Med Assoc J; 2000 Jan; 2(1):22-4. PubMed ID: 10892366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Proliferation of bone marrow hematopoietic stem cells and function of T helper lymphocytes of patients with immuno-related pancytopenia].
    Fu R; Shao ZH; Liu H; He H; Sun J; Zhao MF; He GS; Shi J; Bai J; Yang TY; Yang CL
    Zhonghua Xue Ye Xue Za Zhi; 2004 Apr; 25(4):213-6. PubMed ID: 15182558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The content of lymphopoietic differentiation antigens on the membrane of blood lymphoid cells in patients with bone marrow hypoplasia studied using monoclonal antibodies].
    Miterev GIu; Novikova MS; Bulycheva TI; Turbina NS; Mikhaĭlova EA
    Gematol Transfuziol; 1988 Oct; 33(10):10-5. PubMed ID: 3265120
    [No Abstract]   [Full Text] [Related]  

  • 35. Treating myelodysplastic syndromes.
    Ryan C; McCann S
    IDrugs; 2005 Apr; 8(4):320-6. PubMed ID: 15800807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deviation of type I and type II T cells and its negative effect on hematopoiesis in myelodysplastic syndrome.
    Wu L; Li X; Chang C; Ying S; He Q; Pu Q
    Int J Lab Hematol; 2008 Oct; 30(5):390-9. PubMed ID: 19046314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression.
    Kochenderfer JN; Kobayashi S; Wieder ED; Su C; Molldrem JJ
    Blood; 2002 Nov; 100(10):3639-45. PubMed ID: 12393644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel immunosuppressive strategies for bone marrow failure syndromes: a focus on alemtuzumab.
    Selleri C; Serio B; Risitano AM
    Mini Rev Med Chem; 2011 Jun; 11(6):536-43. PubMed ID: 21561402
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antigen-recognition sites of micromanipulated T cells in patients with acquired aplastic anemia.
    Piao W; Grosse J; Czwalinna A; Ivanyi P; Ganser A; Franzke A
    Exp Hematol; 2005 Jul; 33(7):804-10. PubMed ID: 15963856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determining which patients with myelodysplastic syndrome will respond to immunosuppressive treatment.
    Barrett J; Sloand E; Young N
    Haematologica; 2006 May; 91(5):583-4. PubMed ID: 16670061
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.